By Stephen Nakrosis
Pharmaceutical company Novartis said it plans to expand U.S.-based manufacturing and research and development, with a total investment of $23 billion over the next five years.
The company said it is planning to increase its R&D activity with a new $1.1 billion research hub in the San Diego area, its second in the U.S. The new complex is expected to open between 2028 and 2029.
Novartis also intends to build four new manufacturing facilities, including 3 which will make biologics drug substances, drug products, device assembly and packaging. The other facility will make chemical drug substances, oral solids dosage forms and packaging. The new manufacturing capacity will enable Novartis to produce 100% of its key medicines end-to-end in the U.S., according to the company.
The company also plans to construct a pair of radioligand therapy manufacturing facilities in Florida and Texas, and expand three RLT manufacturing facilities in Indianapolis, Millburn, NJ, and Carlsbad, CA.
The investments will give Novartis manufacturing capacity in the U.S. for all its core technology platforms, including small molecules and biologics, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 10, 2025 14:29 ET (18:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.